Pre-clinical Models for Mesenchymal Stem Cell Therapy in Hemophilic Arthropathy

Last updated: December 24, 2021
Sponsor: University Hospital, Montpellier
Overall Status: Active - Recruiting

Phase

N/A

Condition

Arthritis And Arthritic Pain

Hemophilia

Treatment

N/A

Clinical Study ID

NCT05187936
RECHMPL21_0640
  • Ages > 18
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

Hemophilia is a constitutional coagulation disorder responsible for a hemorrhagic phenotype in patients from an early age. Hemarthrosis is one of the most frequent complications in hemophiliacs and leads to the development of severe and early arthropathy, sometimes as early as childhood. To date, there is no curative treatment for these joint disorders and preventive treatments are insufficient to completely prevent joint degradation. Mesenchymal stem cells have been shown to be of therapeutic interest in the management of pathologies such as osteoarthritis and inflammatory arthritis through their anti-inflammatory, regenerative and anti-apoptotic effects. Hemophilic arthropathy is a separate condition at the border of these two diseases Our study aim to show pre-clinical interest of mesenchymal stem cell therapy in hemophilic arthropathy

Eligibility Criteria

Inclusion

Inclusion criteria:

  • Hemophilia A or B adult patient, with or without arthropathy
  • Heathly control

Exclusion

Exclusion criteria:

  • Antiinflammatory drug use
  • immunosuppressive treatment or condition

Study Design

Total Participants: 200
Study Start date:
October 01, 2021
Estimated Completion Date:
December 31, 2022

Connect with a study center

  • Uhmontpellier

    Montpellier, 34295
    France

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.